Mehdi Gasmi, VP, Pharmaceutical Development at Avalanche Biotechnologies, Inc. ([AAVL]), sold 500 shares at $37.97 ($19K) on 2015-06-08, disclosed to the SEC on 2015-06-10.
Scheduled sale ($19k) by VP, Pharmaceutical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.97 | 235 | $9K | 46.2% |
| 2 | $38.95 | 183 | $7K | 36.9% |
| 3 | $39.88 | 82 | $3K | 16.9% |
| Total | $38.64 avg | 500 | $19K | 100% |
| Filing → |
| ADVM | SELL | 2020-06-18 | $563K | — | Filing → |
| ADVM | SELL | 2020-06-17 | $324K | — | Filing → |
| ADVM | SELL | 2020-05-22 | $100K | — | Filing → |